MREO

0.26423.93%
JB

Jeremy Bender

Independent Non Executive Director

Dr. Jeremy Bender, Ph.D., M.B.A., is Chair of the Board of Diagonal Therapeutics, Inc. from November 2026. Dr. Bender is Independent Director of Bicara Therapeutics Inc. from July 28, 2026. He is Independent Director of Aura Biosciences, Inc. from July 7, 2026. Dr. Bender served as Chief Executive Officer and Director of Day One Biopharmaceuticals, Inc. since September 2020 until April 23, 2026 and served as its President until April 23, 2026. He serves as President, Chief Executive Officer and Director at Day One Biopharmaceuticals Holding Co LLC since September 2020. Dr. Jeremy Bender serves as Independent Director of Fusion Pharmaceuticals Inc. since October 16, 2023. He has been Independent Non Executive Director of Mereo BioPharma Group plc since October 1, 2020. Dr. Bender is a senior biopharma leader with broad experience driving strategic decisions and transactions. He serves as a Director of Day One Biopharmaceuticals Holding Company, LLC and DOT-1 Therapeutics Inc. He serves as Director of Vima Therapeutics, Inc. He served as Vice President of Corporate Development at Gilead Sciences, Inc. from March 2018 to September 2020. to advance next-generation cancer immunotherapies. He served as Chief Operating Officer at Tizona Therapeutics, Inc. from July 2015 to March 2018. Dr. Bender served as the Chief Business Officer of Sutro Biopharma, Inc from October 24, 2012 to August 6, 2015. Dr. Bender has an established track record of global and regional collaborations as well as mergers and acquisitions in the life sciences industry. He was Vice President, corporate development, of Allos Therapeutics, where he was responsible for mergers and acquisitions as well as financing transactions, product in-and out-licensing as well as corporate and strategic planning from January 2006 to September 2012. While at the company, he established a collaboration with Mundipharma for the co-development and commercialization of Folotyn(R) outside the United States and Canada. Prior to joining Allos Therapeutics, he was a project leader at The Boston Consulting Group. Dr. Bender received Ph.D. in microbiology and immunology from the University of Colorado, a master's degree in business administration from MIT Sloan School of Management and a B.S. in Biological Sciences from Stanford University.

Positions